Skip to main content

Table 1 Patient characteristics for GCT-TN cohort within the Em-EP study

From: Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN)

Total number of patients, n (%)

n = 104

Age, years

Median: 35

Mean: 36

Range: 17–71

Gender

 Male

22a (21%)

 Female

82b (79%)

Primary site of disease

 Gonadal, n = 41 (39%)

  Testicular, n = 15 (14%)

Seminoma

4 (4%)

Non-seminomatous GCT

11 (11%)

  Ovarian, n = 26 (25%)

Dysgerminoma

2 (2%)

Non-dysgerminomatous GCTc

24 (23%)

 Uterine, n = 44 (42%)

Gestational trophoblastic neoplasia (GTN)

Hydatidiform mole

19 (18%)

Choriocarcinoma

24 (23%)

Non-gestational choriocarcinoma

1 (1%)

Extra-gonadal, n = 8 (8%)

 Mediastinal

5 (5%)

 Retroperitoneal

1 (1%)

 Sacrococcygeal

1 (1%)

 Pineal

1 (1%)

Other, n = 2 (2%)

 Pulmonaryd

2 (2%)

Unknown primary, n = 9 (8%)

 GCT

2 (2%)

 TN

6 (6%)

 Adenocarcinoma of unknown origine

1 (1%)

  1. a Six male patients harboured seminomas (32%) and 13 non-seminomatous GCTs (68%). In the remaining 3/22 male patients (14%), 1 patient (5%) presented with both a raised serum hCG and a testicular mass, whereas 2 patients (9%) were treated as GCT based on elevated serum tumour markers alone. Primary disease sites for male patients included testicular in 68% (n = 15), extragonadal in 23% (mediastinal, retroperitoneal and pineal; n = 5) and unknown in 9% (n = 2)
  2. b In contrast to their male counterparts, a histological diagnosis was available for all 30 female GCT patients admitted in the acute setting. Subtypes included 2 dysgerminomas (7%) and 28 non-dysgerminomas (97%). This subset excludes non-gestational trophoblastic neoplasia. Primary disease sites were ovarian in 87% (n = 26) and extragonadal in 10% (mediastinal, sacrococcygeal, pulmonary; n = 3). A primary site was unknown in 1 patient (3%)
  3. c One patient with an ovarian primary disease site was diagnosed as an ectopic gestational choriocarcinoma
  4. d Histology: yolk sac tumour; non-gestational epithelioid trophoblastic tumour (excluded from survival analysis)
  5. e Empirical treatment as for GCT due to a high AFP level (excluded from survival analysis)